NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MILPREM-400 is an oral tablet combining conjugated estrogens with meprobamate, a fixed-dose combination product in pre-launch stage. This product addresses hormonal and anxiety-related symptoms in women, leveraging estrogen replacement therapy paired with anxiolytic support. The combination modality targets patients requiring concurrent management of menopausal or hormone-deficiency symptoms alongside mood or anxiety concerns.
Pre-Launch
Pre-launch status offers opportunity to build foundational commercial infrastructure and establish market positioning, though team size remains unknown pending regulatory approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No current job postings are linked to MILPREM-400, reflecting its pre-launch stage. Career opportunity will emerge post-approval, offering roles in brand building, market access, and field execution within Bausch Health's commercial organization.
Brand ManagerField Sales Representative
Worked on MILPREM-400 at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.